Ophthalmic Business News

Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases.

VRDN-001 demonstrated positive preliminary results in the treatment of chronic thyroid eye disease in an ongoing phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.

SpyGlass Pharma secured $90 million in Series C financing to conduct multiple U.S. clinical trials of its drug delivery platform, according to a press release.

Jay S. Duker, MD, has been appointed as CEO of EyePoint Pharmaceuticals, and Nancy S. Lurker has transitioned from CEO to executive vice chair of the board of directors, according to a press release.

An affiliate of Bausch + Lomb acquired the over-the-counter Blink product line of eye and contact lens drops from Johnson & Johnson Vision, according to a press release.

Medicine is a dynamic profession and physicians are at the forefront of health care innovation, consistently pushing boundaries of patient care and driving both industry and practice patterns forward.

Formycon and Klinge Biopharma have submitted a biologics license application for FYB203, a biosimilar for Eylea, to the FDA, according to a press release.

Is this what it’s like to be in junior high school when the new kid asks the prettiest girl to the dance?

Novartis has entered a transaction of up to $2.5 billion to divest ‘front of eye’ ophthalmology assets, including Xiidra, to Bausch + Lomb, according to a company press release.

Patients who received aflibercept 8 mg for diabetic macular edema maintained dosing intervals through 2 years, according to a press release from Regeneron.